Introduction: Mosunetuzumab (Mosun) is a CD20xCD3 T-cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. In pivotal Phase II study (NCT02500407), fixed-duration Mosun demonstrated high rate of complete responses (CRs) and durable in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL) ≥2 prior lines therapy. We report efficacy outcomes for p...
